Patent estate
Ferring Pharmaceuticals — Patent Portfolio
2 drugs with active patents · 3 active patents · 0 expired · 1 biologic with BPCIA exclusivity
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Menopur (MENOTROPINS)
🧬 BPCIA biologic exclusivity to 2016-10-29
Endometrin (progesterone)
Cliff 2029 · 3yFormulation 1 Method of Use 2
-
US10548904
Vuln 75
2029-02-03
This patent protects monolithic intravaginal rings containing progesterone, a method of making them, and their uses.
-
US8580293
Vuln 68
2030-01-21
This patent protects monolithic intravaginal rings containing progesterone, a specific type of vaginal ring used for a specific purpose.
-
US10537584
Vuln 55
2029-02-03
This patent protects monolithic intravaginal rings containing progesterone, a polysiloxane elastomer, and a hydrocarbon or glycerol ester of a fatty acid.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 2 patents
- Formulation 1 patent
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Ferring Pharmaceuticals's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export